Upgrade Your Browser
We no longer support this version of your browser.
We recommend that you upgrade to the latest version of Internet Explorer, Firefox, Chrome or Safari to improve your security and experience using this website.
Return to the course you were viewing
Adlyxine (ad-LIKS-een, lixisenatide) and Ozempic (oh-ZEM-pik, semaglutide) will be the latest "GLP-1 agonists" for type 2 diabetes.
Think of these new meds as similar to Victoza and Trulicity.
They're all injections...and cost at least $120/month.
Pharmacy Technician's Letter Canada includes:
Already a subscriber? Log in
Volume pricing available. Get a quote